EndoCyclic Therapeutics has achieved a significant regulatory milestone for its lead endometriosis drug candidate, ENDO-205. The U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application, enabling the start of human clinical trials. This first-in-class, non-hormonal peptide therapeutic is designed to fundamentally change treatment by targeting the root cause of the disease rather than just its symptoms.
A Novel Approach to Endometriosis Treatment
Unlike current treatments that rely on hormonal modulation to manage symptoms, ENDO-205 is engineered to eliminate endometriosis lesions directly. This innovative approach seeks to address not only pain but also the systemic complications associated with the condition. Its targeted mechanism is designed to act specifically on diseased tissue, thereby minimizing broader systemic side effects and avoiding hormonal manipulation.
The development of ENDO-205 is the culmination of more than a decade of dedicated research on the company's proprietary precision peptide platform. Preclinical investigations have yielded promising results, demonstrating the therapy's ability to eliminate lesions and associated inflammation. Importantly, comprehensive toxicology studies have not identified any significant safety concerns, supporting its advancement into human trials.
Addressing a Significant Unmet Need
Endometriosis is a chronic and progressive condition that impacts an estimated 190 million individuals globally, affecting approximately 10% of women in their reproductive years. The disease is characterized by the growth of endometrial-like tissue outside the uterus, leading to severe pain and infertility. It is also linked to an increased risk of other inflammatory conditions and certain cancers.
Patients often face significant hurdles, including diagnostic delays that can span from four to twelve years, prolonging suffering and potentially worsening outcomes. Current medical options are largely symptomatic and fail to address the underlying biology, leading to high recurrence rates. This treatment gap highlights the urgent need for novel therapies that can offer a more definitive and lasting solution.
A Milestone for Women's Health
Dr. Tanya Petrossian, Founder and CEO of EndoCyclic Therapeutics, stated that the FDA's clearance validates the robust scientific foundation behind the program. She emphasized the milestone as a critical step forward for the millions of women affected by what remains a largely overlooked disease. The company is now focused on advancing ENDO-205 into the clinic to pioneer a new standard of care.
The program's potential has been recognized through substantial support from the National Institutes of Health, including multiple awards and designation as an SBIR Success Story. In 2025, it received a rare perfect impact score for an NIH commercialization grant, underscoring its scientific and commercial viability. The company was also selected as a founding member of the Milken Institute Women's Health Network.
Future Directions and Broader Impact
With the IND application cleared, EndoCyclic Therapeutics is preparing to initiate a Phase 1 clinical study. This initial trial will enroll healthy pre-menopausal women of reproductive age to assess the safety and tolerability of ENDO-205. The results will be crucial for guiding the subsequent phases of clinical development for this promising therapeutic candidate.
Beyond its lead therapeutic, the company is also advancing FemLUNA, an investigational imaging agent for the non-invasive diagnosis of endometriosis. This dual focus on both treatment and diagnostics demonstrates a comprehensive strategy to address unmet needs in women's health. EndoCyclic also plans to leverage its precision peptide platform for applications in oncology and other complex diseases.
The FDA's clearance for ENDO-205 marks a pivotal moment in the pursuit of a more effective treatment for endometriosis. By moving beyond symptom management to target the disease's underlying cause, EndoCyclic Therapeutics offers new hope to a vast and underserved patient population. This advancement represents a significant stride toward transforming the therapeutic landscape for this debilitating global condition.